202 related articles for article (PubMed ID: 17222248)
1. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer.
Ling FC; Baldus SE; Khochfar J; Xi H; Neiss S; Brabender J; Metzger R; Drebber U; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Histopathology; 2007 Jan; 50(2):203-9. PubMed ID: 17222248
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
[TBL] [Abstract][Full Text] [Related]
5. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
6. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
7. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage.
Amano Y; Ishihara S; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Miyake T; Miyaoka Y; Rumi MA; Ishimura N; Adachi K; Kinoshita Y
Aliment Pharmacol Ther; 2004 Oct; 20(7):793-802. PubMed ID: 15379840
[TBL] [Abstract][Full Text] [Related]
8. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
Sonoda R; Naomoto Y; Shirakawa Y; Fujiwara Y; Yamatsuji T; Noma K; Tanabe S; Takaoka M; Gunduz M; Tsujigiwa H; Nagatsuka H; Ohara N; Yoshino T; Takubo K; Vieth M; Tanaka N
Histopathology; 2010 Jul; 57(1):90-100. PubMed ID: 20653782
[TBL] [Abstract][Full Text] [Related]
9. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Konturek PC; Kania J; Burnat G; Hahn EG
J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
[TBL] [Abstract][Full Text] [Related]
10. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
11. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
[TBL] [Abstract][Full Text] [Related]
12. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
[TBL] [Abstract][Full Text] [Related]
14. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
[TBL] [Abstract][Full Text] [Related]
15. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
[TBL] [Abstract][Full Text] [Related]
16. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
[TBL] [Abstract][Full Text] [Related]
18. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study.
Whittles CE; Biddlestone LR; Burton A; Barr H; Jankowski JA; Warner PJ; Shepherd NA
J Pathol; 1999 Apr; 187(5):535-40. PubMed ID: 10398118
[TBL] [Abstract][Full Text] [Related]
20. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.
Koss K; Harrison RF; Gregory J; Darnton SJ; Anderson MR; Jankowski JA
J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
